CRS3123

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Crestone, Inc

Conditions

Clostridioides Difficile InfectionClostridium Difficile ColitisClostridium Difficile Infection

Phase 1

Phase I Trial of a Single Dose of CRS3123

CompletedNCT01551004

National Institute of Allergy and Infectious Diseases (NIAID)Clostridium Difficile Colitis

Start: 2012-05-22End: 2014-04-21Updated: 2017-09-25

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

CompletedNCT02106338

National Institute of Allergy and Infectious Diseases (NIAID)Clostridium Difficile Infection

Start: 2014-06-30End: 2014-12-31Target: 36Updated: 2016-06-13

Phase 2

Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection

CompletedNCT04781387

Crestone, IncClostridioides Difficile Infection

Start: 2021-01-05End: 2024-04-16Updated: 2026-03-27

Related Papers

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.

2026-01-22

Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.

2019-12-2027 citations

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123, a Methionyl-tRNA Synthetase Inhibitor Developed for Treatment of Clostridium difficile, in a Phase 1 Study

Antimicrobial Agents and Chemotherapy2017-06-0648 citations